Format

Send to

Choose Destination
Bioanalysis. 2016 Dec;8(23):2475-2496.

2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 3 - LBA, biomarkers and immunogenicity).

Author information

1
Sanofi, Framingham, MA, USA.
2
Bristol-Myers Squibb, Princeton, NJ, USA.
3
Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland.
4
Regeneron Pharmaceuticals, Tarrytown, NY, USA.
5
Genentech, South San Francisco, CA, USA.
6
Roche Pharma Research and Early Development, Roche Innovation Center, Munich, Germany.
7
Angelini Pharma, Pomezia, RM, Italy.
8
Charles River, Reno, NV, USA.
9
Janssen R&D, Spring House, PA, USA.
10
Bioagilytix Labs, Durham, NC, USA.
11
LGC, Cambridge, UK.
12
Daiichi Sankyo, Edison, NJ, USA.
13
Health Canada, Ottawa, ON, Canada.
14
WHO, Geneva, Switzerland.
15
Pfizer, Groton, CT, USA.
16
Italy AIFA, Rome, Italy.
17
Pfizer, Andover, MA, USA.
18
Allergan, Irvine, CA, USA.
19
US FDA, Silver Spring, MD, USA.
20
GlaxoSmithKline, Paoli, PA, USA.
21
Japan MHLW-NIHS, Tokyo, Japan.
22
Eurofins Bioanalytical Services, St Charles, MO, USA.
23
Sanofi, Frankfurt am Main, Germany.
24
Covance, Indianapolis, IN, USA.
25
Brazil Anvisa, Brasilia, Brazil.
26
Novimmune, Geneva, Switzerland.
27
Shire, Lexington, MA, USA.
28
Q2 Solutions, Marietta, GA, USA.
29
CFABS, Laval, QC, Canada.
30
UCB Biopharma, Braine L'Alleud, Belgium.
31
Biogen, Cambridge, MA, USA.
32
Amgen, Thousand Oaks, CA, USA.
33
EMD Serono, Aubonne, Switzerland.
34
Novartis Pharma, Basel, Switzerland.
35
Dutch MEB, Utrecht, The Netherlands.
36
Aduro Biotech, Berkeley, CA, USA.
37
OncoMed Pharmaceuticals, Redwood City, CA, USA.

Abstract

The 2016 10th Workshop on Recent Issues in Bioanalysis (10th WRIB) took place in Orlando, Florida with participation of close to 700 professionals from pharmaceutical/biopharmaceutical companies, biotechnology companies, contract research organizations, and regulatory agencies worldwide. WRIB was once again a weeklong event - A Full Immersion Week of Bioanalysis for PK, Biomarkers and Immunogenicity. As usual, it is specifically designed to facilitate sharing, reviewing, discussing and agreeing on approaches to address the most current issues of interest including both small and large molecules involving LCMS, hybrid LBA/LCMS, and LBA approaches, with the focus on PK, biomarkers and immunogenicity. This 2016 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop, and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to enable advances in scientific excellence, improved quality and better regulatory compliance. This White Paper is published in 3 parts due to length. This part (Part 3) discusses the recommendations for large molecule bioanalysis using LBA, biomarkers and immunogenicity. Parts 1 (small molecule bioanalysis using LCMS) and Part 2 (Hybrid LBA/LCMS and regulatory inputs from major global health authorities) have been published in the Bioanalysis journal, issues 22 and 23, respectively.

PMID:
27855512
DOI:
10.4155/bio-2016-4989
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center